Skip to main content
All lobbying filings

THE GIBSON GROUP, LLC

THE GIBSON GROUP, LLC filed a Q1 report for ASSOCIATION FOR ACCESSIBLE MEDICINES on April 9, 2026, reporting $60,000 in lobbying income.

Lobbying for ASSOCIATION FOR ACCESSIBLE MEDICINES · National trade organization representing the interests of generic drug manufacturers.

All filings by THE GIBSON GROUP, LLC · Everything ASSOCIATION FOR ACCESSIBLE MEDICINES has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 9, 2026
Income
$60,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 1
  • JOSEPH H GIBSON
    Previously held: Counsel for Legislative & Intergovernmental Affairs Anti-Trust Division, DOJ 2001-2002; Chief Antitrust Counsel, House Judiciary Committee 1997-2001; Counsel, House Judiciary Committee 1995-1997

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4
Health Issues

Drug competition issues Monitor drug supply chain issues

Labor Issues/Antitrust/Workplace

Drug competition issues

Copyright/Patent/Trademark

Monitor S. 1096 - patent settlements Issues relating to review of pharmaceutical patents in inter partes reviews Issues relating to the Patent Trial and Appeal Board Patent thickets - S. 1041 Monitor S. 1040 - product hopping Skinny labeling issues Monitor issues relating to the Patent Eligibility Restoration Act Monitor issues relating to the PREVAIL Act

Trade (domestic/foreign)

Monitor issues related to trade agreeements

 Bills named in this filing 3
  • S. 1096
    Preserve Access to Affordable Generics and Biosimilars Act
  • S. 1041
    Affordable Prescriptions for Patients Act
  • S. 1040
    Drug Competition Enhancement Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem